Clinical Trials

To understand why patients with indigestion with or without diabetes have gastrointestinal symptoms and in particular to understand where the symptoms are related to increased sensitivity to nutrients.

The purpose of this study is to compare the effects of secretin vs. saline on satiation, fasting gastric volume, gastric accommodation and emptying, and symptoms in patients with functional dyspepsia with normal gastric emptying and with that of healthy volunteers.

This study is to evaluate the effectiveness of the investigational drug motilitone at 90 mg in patients with functional dyspepsia as measured by change in maximum tolerated volume and the aggregate symptom score on the nutrient drink test.

The purpose of this study is to to evaluate the effectiveness and safety of cannabidiol for gastroparesis and functional dyspepsia.

To understand the utility of measuring stomach emptying, symptoms during a stomach emptying, and blood markers of body metabolism.

The purpose of this study is to evaluate the safety and effectiveness of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard-dose proton pump inhibitors (PPIs).

The purpose of this study is to develop a resource (bank) of biospecimens and data collected from individuals with functional gastrointestinal disorders (FGID) to facilitate discovery and development of novel microbial biomarkers of disease and response to treatment, and novel targeted therapeutic strategies for FGID.  

The purpose of this study is to understand why patients with indigestion, with or without diabetes, have gastrointestinal symptoms and, in particular, to understand where the symptoms are related to increased sensitivity to nutrients.Subsequently, look at the effects of Ondansetron on these patients' symptoms.

The purpose of this study is to understand the day-to-day variability in stomach emptying and gastrointestinal (GI) transit in patients with digestive symptoms. This information will be useful for interpreting the results of stomach emptying studies in future.

The purpose of this study is to:

1. To evaluate the pharmacogenomic profile (PGx) by genotyping 22 genes, including the CYP2D6 genotype, in patients with functional GI disorders.
2. To assess the impact of PGx testing on prescriber patterns in this practice.
3. To explore the impact of PGx testing on patient outcomes after an assessment in this practice.